Quick Answer
Context Therapeutics Inc. reported Shares Outstanding of 91.88 million shares for fiscal year 2025.
Context Therapeutics Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 91.88M | +2.4% |
| 2024 | 89.70M | +461.8% |
| 2023 | 15.97M | +0.0% |
| 2022 | 15.97M | +0.0% |
| 2021 | 15.97M | +4712.1% |
| 2020 | 331,789 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 91.88M | +22.5% | +2.4% |
| June 30, 2025 | 89.70M | +19.6% | +0.0% |
| March 31, 2025 | 89.70M | +461.8% | +0.0% |
| December 31, 2024 | 89.70M | +461.8% | +19.6% |
| September 30, 2024 | 75.00M | +369.7% | +0.0% |
| June 30, 2024 | 75.00M | +369.7% | +369.7% |
| March 31, 2024 | 15.97M | +0.0% | +0.0% |
| December 31, 2023 | 15.97M | +0.0% | +0.0% |
- Context Therapeutics Inc. showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Context Therapeutics Inc.’s shares outstanding has grown by 27592.1% (from 331.8 thousand shares to 91.88 million shares).
- The most recent figure is from Context Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: